Orexo announces positive data for powder-based intranasal vaccine formulated with the AmorphOX technology
Orexo AB (publ.), a Swedish pharmaceutical company, has announced the positive in-vivo proof-of-concept data for a powder-based intranasal vaccine candidate formulated with the AmorphOX technology. The data was generated under the collaboration between …